Summary
The product ARI TAB, with an unknown manufacturer and batch number 3/29, was independently tested to verify its authenticity and potency. The sample was submitted by the client biogenixpharma and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Anastrozole, with a concentration of 1.15 mg, which is 15% above the labeled claim of 1 mg.
The testing process was conducted on 16 April 2024. The results indicate a slight overdosing, which may be due to natural variances in pharmaceutical production. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Biogenixpharma
- Product Name: ARI TAB
- Active Ingredient: Anastrozole
- Batch Number: 3/29
- Expiration Date: Not provided
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #40986
- Testing Ordered: 2 April 2024
- Sample Received: 12 April 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Optitropin.EU (Reseller)
- Analysis Paid For By: Optitropin.EU
Testing Results
- Specification: 1 mg (as stated on the label)
- Measured Concentration: 1.15 mg
- Accuracy: 115% (15% above the label claim)
- Variance: +15%
Verification Details
- Verification URL: https://janoshik.com/tests/40986_AL66KNQZHF7Y
Evaluation of Client-Submitted Testing
This analysis highlights the slight overdosing of the tested product, which may be due to natural variances in pharmaceutical production. While the results are within an acceptable range, it is important to note that client-submitted samples may not fully represent the consistency of the product across all batches. Independent third-party testing remains crucial to validate these findings comprehensively.
Conclusion
The analysis confirms that ARI TAB is slightly overdosed, with a measured concentration of 1.15 mg. This result reflects reasonable quality control for this batch but underscores the importance of additional testing to ensure consistent dosing across the product line. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding pharmaceutical products.
Disclaimer
This report is published for educational and harm reduction purposes. Client-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
